La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
77 hedge funds and large institutions have $76.8M invested in La Jolla Pharmaceutical Company in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 16 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3% more funds holding
Funds holding: 75 → 77 (+2)
2% more call options, than puts
Call options by funds: $294K | Put options by funds: $289K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less capital invested
Capital invested by funds: $219M → $76.8M (-$142M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$14.8M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.68M |
| 4 |
RI
RTW Investments
New York
|
+$1.6M |
| 5 |
Goldman Sachs
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$13.7M |
| 3 |
VMI
VHCP Management III
New York
|
-$11M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.2M |
| 5 |
VMI
VHCP Management II
New York
|
-$4.56M |
LJPC Hedge Fund Activity: Q4 2019 in Review
77 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2019, worth a combined $76.8M — down 65% from $219M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new LJPC positions and 16 closed out — a net gain of 3 holders — while 24 added to existing stakes and 19 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $14.8M. The largest seller was Fidelity Investments, cutting an estimated $16.6M.
- 77 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2019, up from 75 in Q3 2019.
- Funds reported $76.8M of La Jolla Pharmaceutical Company stock for Q4 2019, down 65% quarter-over-quarter.
- 19 funds opened new La Jolla Pharmaceutical Company positions in Q4 2019 and 16 closed out, a net change of +3 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q4 2019 was Broadfin Capital, an estimated $14.8M added.
- The largest La Jolla Pharmaceutical Company seller in Q4 2019 was Fidelity Investments, an estimated $16.6M sold.
Based on aggregated 13F filings for Q4 2019.